SDF-1 Binding Nucleic Acids and the Use Thereof
AssigneeNOXXON Pharma AG
InventorsWerner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
Life of this patent
Estimating the term…
Abstract
The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
Claims21
1-115. (canceled)
A method for the treatment of nephropathy or hypertension, wherein the method comprises administering to a subject in need of treatment, a nucleic acid that inhibits the signalling between SDF-1 and the SDF-1 receptor.
A method for inhibiting the migration of leukocytes, wherein the method comprises administering to a subject in need of treatment a nucleic acid that inhibits signalling between SDF-1 and the SDF-1 receptor selected from the group consisting of a type A nucleic acid, a type B nucleic acid, a type C nucleic acid, SEQ ID NO:142, SEQ ID NO:
- 143 and SEQ ID N:144,
- wherein the type A nucleic acid comprises a core nucleotide sequence:
- (SEQ ID NO:
- 19)
- 5′ AAAGYRACAHGUMAAXAUGAAAGGUARC 3′
- wherein XA is either absent or is A,
- wherein the type B nucleic acid molecule comprises a core nucleotide sequence:
- (SEQ ID NO:
- 57)
- 5′ GUGUGAUCUAGAUGUADWGGCUGWUCCUAGUYAGG 3′;
- and
- wherein the type C nucleic acid molecule comprises a core nucleotide sequence of
- (SEQ ID NO:
- 90)
- GGUYAGGGCUHRXAAGUCGG,
- wherein XA is either absent or is A.
Dependencies are inferred from the claim text.